Seaward Management Limited Partnership Continues to Hold Stake in Celgene Corporation (CELG)

Seaward Management Limited Partnership held its position in Celgene Corporation (NASDAQ:CELG) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,518 shares of the biopharmaceutical company’s stock at the close of the second quarter. Seaward Management Limited Partnership’s holdings in Celgene Corporation were worth $327,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of CELG. Neuberger Berman Group LLC increased its holdings in shares of Celgene Corporation by 4.0% during the 1st quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock valued at $229,553,000 after purchasing an additional 71,729 shares in the last quarter. Lincoln Capital Corp increased its holdings in shares of Celgene Corporation by 0.6% during the 2nd quarter. Lincoln Capital Corp now owns 30,580 shares of the biopharmaceutical company’s stock valued at $3,971,000 after purchasing an additional 185 shares in the last quarter. Swiss National Bank increased its holdings in shares of Celgene Corporation by 27.2% during the 1st quarter. Swiss National Bank now owns 2,746,896 shares of the biopharmaceutical company’s stock valued at $341,796,000 after purchasing an additional 588,000 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Celgene Corporation by 9.2% during the 2nd quarter. Russell Investments Group Ltd. now owns 641,697 shares of the biopharmaceutical company’s stock valued at $83,344,000 after purchasing an additional 54,210 shares in the last quarter. Finally, Iguana Healthcare Management LLC increased its holdings in shares of Celgene Corporation by 12.5% during the 1st quarter. Iguana Healthcare Management LLC now owns 90,000 shares of the biopharmaceutical company’s stock valued at $11,199,000 after purchasing an additional 10,000 shares in the last quarter. 79.36% of the stock is owned by institutional investors.

In related news, Director Ernest Mario sold 18,506 shares of the stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the sale, the director now owns 69,424 shares of the company’s stock, valued at $9,061,220.48. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Terrie Curran sold 1,727 shares of the stock in a transaction on Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the sale, the insider now directly owns 3,925 shares in the company, valued at approximately $564,768.25. The disclosure for this sale can be found here. Insiders sold 46,233 shares of company stock worth $6,268,259 in the last three months. 0.95% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: “Seaward Management Limited Partnership Continues to Hold Stake in Celgene Corporation (CELG)” was first published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://transcriptdaily.com/2017/10/08/seaward-management-limited-partnership-continues-to-hold-stake-in-celgene-corporation-celg.html.

CELG has been the subject of several recent research reports. BTIG Research lowered shares of Celgene Corporation from a “buy” rating to a “neutral” rating and lifted their target price for the company from $96.93 to $131.70 in a report on Friday, June 30th. Leerink Swann reaffirmed an “outperform” rating and set a $160.00 target price (up from $150.00) on shares of Celgene Corporation in a report on Friday, July 28th. Argus raised shares of Celgene Corporation from a “hold” rating to a “buy” rating and lifted their target price for the company from $96.93 to $160.00 in a report on Monday, July 31st. Credit Suisse Group set a $148.00 target price on shares of Celgene Corporation and gave the company a “buy” rating in a report on Thursday, July 6th. Finally, Stifel Nicolaus initiated coverage on shares of Celgene Corporation in a report on Friday, July 28th. They set a “buy” rating and a $155.00 target price for the company. Two analysts have rated the stock with a sell rating, five have given a hold rating and twenty-two have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $150.60.

Shares of Celgene Corporation (NASDAQ CELG) opened at 139.21 on Friday. The firm has a market cap of $108.91 billion, a PE ratio of 43.11 and a beta of 1.88. Celgene Corporation has a 52 week low of $96.93 and a 52 week high of $147.17. The firm’s 50-day moving average is $139.31 and its 200 day moving average is $129.53. Celgene Corporation also saw some unusual options trading on Thursday. Traders acquired 12,607 put options on the stock. This is an increase of approximately 260% compared to the average volume of 3,499 put options.

Celgene Corporation (NASDAQ:CELG) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.61 by $0.21. The company had revenue of $3.27 billion for the quarter, compared to analyst estimates of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. Celgene Corporation’s revenue was up 18.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.44 earnings per share. Equities research analysts forecast that Celgene Corporation will post $7.32 EPS for the current year.

Celgene Corporation Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply